Latest Articles
Is Recurrent Endometriosis a Reprogrammed Disease? Molecular Persistence Beyond Surgical Clearance.
Background: Endometriosis is traditionally conceptualized as a localized gynecological disorder characterized by the presence of ectopic endometrial tissue. However, high recurrence rates following apparently complete surgical excision challenge this lesion-based …
Published: May 21, 2026, midnight
Primary Cutaneous Endometriosis of the Umbilicus: A Diagnostic Challenge.
Umbilical endometriosis, or Villar's nodule, is a rare form of cutaneous endometriosis in which ectopic endometrial tissue involves the umbilical skin. It may occur without any history of abdominal or …
Published: May 21, 2026, midnight
New treatment offers hope for endometrial cancer patients - New York Post
New treatment offers hope for endometrial cancer patients New York Post
Published: May 20, 2026, 6:34 p.m.
How Investors Are Reacting To Merck (MRK) TroFuse ADC’s Breakthrough Endometrial Cancer Phase 3 Trial Results - Yahoo Finance
How Investors Are Reacting To Merck (MRK) TroFuse ADC’s Breakthrough Endometrial Cancer Phase 3 Trial Results Yahoo Finance
Published: May 20, 2026, 6:22 p.m.
Recognizing and Managing Immune-Related Adverse Events in Endometrial Cancer - OncLive
Recognizing and Managing Immune-Related Adverse Events in Endometrial Cancer OncLive
Published: May 20, 2026, 2:57 p.m.
New therapy bests chemo to improve survival in endometrial cancer - Rare Cancer News
New therapy bests chemo to improve survival in endometrial cancer Rare Cancer News
Published: May 20, 2026, 1:14 p.m.
GIST, SNUH identify beneficial bacterium linked to lower endometrial cancer recurrence - koreabiomed.com
GIST, SNUH identify beneficial bacterium linked to lower endometrial cancer recurrence koreabiomed.com
Published: May 20, 2026, 7:57 a.m.
Merck's Sac-TMT meets both endpoints in phase 3 endometrial cancer trial - MSN
Merck's Sac-TMT meets both endpoints in phase 3 endometrial cancer trial MSN
Published: May 20, 2026, 6:16 a.m.
How Sacituzumab Trial Success In Endometrial Cancer At Merck (MRK) Has Changed Its Investment Story - simplywall.st
How Sacituzumab Trial Success In Endometrial Cancer At Merck (MRK) Has Changed Its Investment Story simplywall.st
Published: May 20, 2026, 5:46 a.m.
It has been revealed why the recurrence rate of endometrial cancer, one of the representative female.. - 매일경제
It has been revealed why the recurrence rate of endometrial cancer, one of the representative female.. 매일경제
Published: May 20, 2026, 4:30 a.m.
Link copied to clipboard!